References
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th. ( DSM–5). Arlington, VA: American Psychiatric Publishing; 2013.
- Jellinger KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies. J Neural Transm (Vienna). 2018;125:615–650.
- McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88–100.
- Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2019 September 10. DOI: 10.1016/S1474-4422(19)30153-X.
- Palermo G, Ceravolo R, Bonuccelli U. Advances in the pharmacotherapeutic management of dementia with Lewy bodies. Expert Opin Pharmacother. 2018;19:1643–1653.
- Hershey LA, Coleman-Jackson R. Pharmacological management of dementia with Lewy bodies. Drugs Aging. 2019;36:309–319.
- Verny M, Blanc F. Lewy body dementia: therapeutic propositions according to evidence based medicine and practice. Geriatr Psychol Neuropsychiatr Vieil. 2019;17:189–197.
- Tahami Monfared AA, Meier G, Perry R, et al. Burden of disease and current management of dementia with Lewy bodies: A literature review. Neurol Ther. 2019;8:289–305.
- Connors MH, Quinto L, McKeith I, et al. Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychol Med. 2018;48:1749–1758.
- Morrin H, Fang T, Servant D, et al. Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia. Int Psychogeriatr. 2018;30:395–407.
- Meng YH, Wang PP, Song YX, et al. Cholinesterase inhibitors and memantine for Parkinson’s disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med. 2019;17:1611–1624.
- Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172:731–742.
- Murata M, Odawara T, Hasegawa K, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study. Neurology. 2018;90:e664–e672.
- Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front Molec Neurosci. 2019;12:299.
- Fernandez-Valle T, Gabilondo I, Gomez-Esteban JC. New therapeutic approaches to target alpha-synuclein in Parkinson’s disease: the role of immunotherapy. Int Rev Neurobiol. 2019;146:281–295.
- Mandler M, Rockenstein E, Overk C, et al. Effects of single and combined immunotherapy approach targeting amyloid beta protein and alpha-synuclein in a dementia with Lewy bodies-like model. Alzheimers Dement. 2019;15:1133–1148.
- Peterson B, Armstrong M, Galasko D, et al. Lewy body dementia association’s research centers of excellence program: inaugural meeting proceedings. Alzheimers Res Ther. 2019;11:23.